Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $2.6 million.

  • Lyell Immunopharma's Depreciation & Amortization (CF) fell 4517.09% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year decrease of 2794.22%. This contributed to the annual value of $19.6 million for FY2024, which is 305.68% down from last year.
  • Per Lyell Immunopharma's latest filing, its Depreciation & Amortization (CF) stood at $2.6 million for Q3 2025, which was down 4517.09% from $3.1 million recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Depreciation & Amortization (CF) peaked at $5.1 million during Q3 2023, and registered a low of $2.0 million during Q1 2021.
  • For the 5-year period, Lyell Immunopharma's Depreciation & Amortization (CF) averaged around $4.2 million, with its median value being $4.6 million (2022).
  • In the last 5 years, Lyell Immunopharma's Depreciation & Amortization (CF) skyrocketed by 27056.16% in 2021 and then tumbled by 4517.09% in 2025.
  • Quarter analysis of 5 years shows Lyell Immunopharma's Depreciation & Amortization (CF) stood at $4.6 million in 2021, then rose by 10.43% to $5.0 million in 2022, then rose by 0.32% to $5.1 million in 2023, then fell by 0.61% to $5.0 million in 2024, then crashed by 48.95% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $3.1 million for Q2 2025, and $3.4 million during Q1 2025.